Since the beginning of this millennium we have seen antibiotic R&D dwindle year after year. There are many reasons for this; while economics are often cited for this decline, the FDA and the ‘Guideline Wars’, i.e., those never ending discussions Continue reading Progress Report: New Antibacterials In the Fight against MDR Bacteria
The economics of developing antibacterials is a frustrating topic to address. There are unique aspects to the antibiotic market which sets it apart from other medicines, esp. the unique societal aspects of antibiotic use which go beyond the benefit to Continue reading It’s Not a Free-Enterprise Market, Stupid!
A recent publication  from the team which brought us the Meningococcal B vaccine is of interest from the perspective of vaccine development strategy and feasibility. Link to this post!